Parissenti, A. M., Pritzker, L. B., Dahle, M. A., Gythfeldt, H. v. d. L., Masilamani, T., Theriault, G., . . . Engebraaten, O. High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy. BMC.
Chicago Style (17th ed.) CitationParissenti, Amadeo M., et al. High Mid-treatment Tumour RNA Disruption in Patients with HER2-negative Breast Cancer Is Associated with Improved Disease-free Survival After Neoadjuvant Chemotherapy. BMC.
MLA (9th ed.) CitationParissenti, Amadeo M., et al. High Mid-treatment Tumour RNA Disruption in Patients with HER2-negative Breast Cancer Is Associated with Improved Disease-free Survival After Neoadjuvant Chemotherapy. BMC.
Warning: These citations may not always be 100% accurate.